# rosacea FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/rosacea

> No upcoming FDA catalysts in rosacea; 3 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Mar 2023 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | rosacea | completed, positive | "In March 2023, we announced positive topline results from the Phase 1 Galatea trial (the "Galatea Phase 1 trial") and initiated a Phase 2a trial (the "Galatea trial") for the potential treatment of papulopustular rosacea." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000019/tars-20251231.htm)) |
| Feb 2024 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | rosacea | completed, positive | "In February 2024, we announced positive topline results from the Galatea trial, a Phase 2a trial evaluating TP-04, an investigational sterile aqueous gel formulation of lotilaner, for the potential treatment of papulopustular rosacea, for which Demodex mites is believed to be one of the root causes." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000076/tars-20260930.htm)) |
| Feb 2024 | [Tarsus Pharmaceuticals, Inc. topline data readout](https://sec-api.dev/companies/tars/catalysts) | TARS | rosacea | completed, positive | "In February 2024, we announced positive topline results from the Carpo Trial, which demonstrated a statistically significant increase in tick mortality compared to vehicle (p<0.001), regardless of treatment arm, and was well tolerated (the "Carpo Trial")." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1819790/000181979026000076/tars-20260930.htm)) |

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/rosacea.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "rosacea FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/rosacea

```bibtex
@misc{secapidev_indications_rosacea_20261116,
  title        = {rosacea FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/rosacea}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_rosacea_20261116","title":"rosacea FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/rosacea","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
